Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa®

October 10, 2010 By Bio-Medicine.Org

THOUSAND OAKS, Calif., Oct. 10 /PRNewswire-FirstCall/ — Amgen
(Nasdaq:  AMGN) today announced results from two integrated
analyses of head-to-head pivotal Phase 3 trials comparing denosumab
to Zometa® (zoledronic acid), the current standard of care in
the prevention of skeletal related events (SREs) in patients with
advanced malignancies involving bone. In these separate analyses,
denosumab demonstrated a clinically meaningful, consistent and
robust treatment effect across tumor types in the reduction of
SREs, and also prevented clinically relevant increases in pain,
compared with Zometa. A separate presentation highlighted the
meaningful burden that SREs pose to the healthcare system. These
analyses were presented at the 35th European Society for Medical
Oncology (ESMO) Congress being held in Milan, Italy.

“Bone metastases and their subsequent complications, such as a
fracture, are devastating events for advanced cancer patients and
costly to the healthcare system,” said Allan Lipton, M.D.,
professor of Medicine & Oncology, M.S. Hershey Medical Center
of the Pennsylvania State University. “This analysis of the largest
registration program ever undertaken in bone metastases
demonstrates that denosumab can offer a clinical advance over
Zometa in delaying or preventing these bony complications, as well
as the pain that frequently results from them. These efficacy gains
coupled with the convenience of a subcutaneous injection and no
need for renal monitoring make denosumab an attractive option for
these patients.”

Integrated Analysis Reveals Denosumab Superior to Zometa In
Delaying or Preventing Time to First-and-Subsequent Skeletal
Related Event Across a Broad Cancer Population with Bone
MetastasesThe effect of denosumab versus Zometa was evaluated in
three large, identically designed Phase 3 trials that enrolled
patients with bone metastases and breast cancer, prostate cancer or
other solid tumors and multiple myeloma. The integrat

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech